"the Company plans to commence a Phase II trial to further validate these findings and explore
additional therapeutic indications for R327. The Phase II study is expected to be across 30
patients with the aim to confirm the efficacious potential of R327 among more diverse
populations, ensuring robust and comprehensive data to support its clinical development."
Sounds like they are doing another Phase I and wasting time on alternate applications to me.
Still no talk of a proper phase II with actual clinical populations.
(20min delay)